StockIQpro
NASDAQ:RXRX

Recursion Pharmaceuticals, Inc.

Track all markets on TradingView
Track all markets on TradingView

Recursion Pharmaceuticals, Inc.'s revenue grew 26.9% in fiscal 2025 to $74.7M while operating margin fell to −867.9%. Free cash flow was −$378.3M, −506.5% of revenue, and the diluted share count rose 63.2%.Summary generated from Recursion Pharmaceuticals, Inc.'s SEC filings. Latest annual report filed Feb 25, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$74.7M
Revenue growth+26.9%
Revenue, 5-yr CAGR+79.9%
Gross margin5.0%
Operating margin−867.9%
Net margin−863.4%
ROIC−117.2%
Return on equity−59.5%
Debt / equity0.02
Free cash flow−$378.3M
FCF margin−506.5%
Share count change+63.2%

Financials

Fiscal years, $M
Item20212022202320242025
Revenue1040455975
Operating income−183−246−350−479−648
Net income−186−239−328−464−645
Free cash flow−198−121−300−373−378

Recent filings

From SEC EDGAR

Peers

Biological products, (no diagnostic substances)